

PTC/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
k Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subs	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/614,990-Conf. #8196	
IN	<b>IFORMATIO</b>	N DIS	CLOSURE	Filing Date	July 9, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Henrik S. Olsen	
				Art Unit	1647	
	(Use as many sheets as necessary)			Examiner Name	C. J. Nichols	
Sheet	1	of	3	Attorney Docket Number	PF108P2D1	

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( If Innown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where ' Relevant Passages or Relevant Figures Appear
છુ	BA	US-09/912,292	PUBLISHED	Rosen et al.	Pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS:23831 and 23838.
ري	ВВ	US-09/912,293	PUBLISHED	Rosen et al.	Pages 1-75 (pages 1 & 2 partially redacted); portion of Table 2; and SEQ ID NOS: 62913 and 194330.
8	ВС	US-2002/0137081	09-26-2002	Olga Bandman	
$\mathcal{C}_{\infty}$	BD	US-5,877,290	03-02-1999	Oisen et al.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\*CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filling date under 35 U.S.C. 120. 'Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature Date Considered 4705



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006, OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/614,990-Conf. #8196 INFORMATION DISCLOSURE July 9, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Henrik S. Olsen Art Unit 1647 (Use as many sheets as necessary) **Examiner Name** C. J. Nichols 2 Sheet 3 of PF108P2D1 Attorney Docket Number

		FOREI	GN PATENT D	OCUMENTS	······································	
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>6</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵
600	BE WO-96/13610		05-09-1996	Geron Corp.		
	BF	WO-98/20165	05-14-1998	Whitehead Institute for Biomedical Research		
	BG	WO-00/16795	03-30-2000	Snow Brand Milk Products Co., Ltd.	Abstract and SEQ ID NOS:3 and 4.	
	ВН	WO-00/55174	09-21-2000	Human Genome Sciences, Inc.	Pages 1-612 of Specification and pages 342-343 and 1244-1245 of Sequence Listing containing SEQ ID NOS: 486 and 1426.	
	ВІ	WO-01/30969	05-03-2001	Human Genome Sciences, Inc.		
	BJ	WO-01/32209	05-10-2001	Diadexus, Inc.		_
	ВК	WO-01/40269	06-07-2001	Corixa Corp.		
	BL	WO-01/57271	08-09-2001	Aeromica, Inc.		=
	ВМ	WO-02/04013	01-17-2002	BML, Inc.	Abstract and Figures, esp. Figure 1.	
	BN	WO-02/060317	08-08-2002	Corixa Corp.		$\blacksquare$
	ВО	WO-02/074979	09-26-2002	Ortho-Clinical Diagnostics, Inc.	Complete Specification and Figures and page 28 of Sequence Listing containing SEQ ID NO:36.	
3	BP	WO-02/085308	10-31-2002	Epigenesis Pharmaceuticals, Inc.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (\*') next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filling date under 35 U.S.C. 120. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.usato.gov">www.usato.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Auros	Date Considered	417105



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/614,990-Conf. #8196	
- 11	<b>NFORMATIO</b>	N DI	SCLOSURE	Filing Date	July 9, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Henrik S. Olsen	
			•	Art Unit	1647	
	(Use as many sheets as necessary)			Examiner Name	C. J. Nichols	
Sheet	3	of	3	Attorney Docket Number	PF108P2D1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
دوي	BQ	WAGNER, et al., "Immunological and biological evidence for a stanniocalcin-like hormone in human kidney," <i>Proc. Natl. Acad. Sci. USA</i> 92:1871-1875 (Mar. 1995).	_
	BR	YAMASHITA et al., "The complete amino acid sequence of chum salmon stanniocalcin, a calcium-regulating hormone in teleosts," <i>Molec. and Cell. Endocrin.</i> 112:159-167 (1995)	
	BS	SUNDELL et al., "Chum salmon (Oncorhynchus keta) stanniocalcin inhibits in vitro intestinal calcium uptake in Atlantic cod (Gadus morhua)," <i>J. Comp. Physiol. B</i> 162:489-495 (1992)	
	ВТ	HULOVA et al., "Assignment of Disulfide Linkages in Chum Salmon Stanniocalcin" Biochem. and Biophys. Res. Comm. 257:295-299 (1999)	
	BU	GenBank Accession No. AF242179, JEFFREY et al., "Homo sapiens stanniocalcin 1 (STC1) gene, exons 1 through 4 and complete cds" (Feb. 21, 2002)	
	BV	GenBank Accession No. AF257506, G.E. DIMATTIA, "Bos taurus stanniocalcin mRNA, complete cds" (May 9, 2000)	
	BW	GenBank Accession No. AZ754534, BARBER et al., "cq01b02.f1 Pax3 CASTing Library 'cq' Mus musculus genomic clone cq01b02 random, genomic survey sequence" (Mar. 1, 2001)	_
دوے	BX	GenBank Accession No. BH042878, ZHAO et al., "RPCI-24-313A13.TJ RPCI-24 Mus musculus genomic clone RPCI-24-313A13, genomic survey sequence" (Jul. 17, 2001)	_

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ond to a collection of information unless it contains a valid OMB control number.

Sul	ostitute for form 1449A/P	то		Complete If Known		
				Application Number	09/840,989	
11	VFORMATIC	ON DIS	CLOSURE	Filing Date	April 25, 2001	
5	STATEMENT	ΓBY A	PPLICANT	First Named Inventor	Henrik S. Olsen	
i				Art Unit	1647	
	(use as many	sheets as n	ecessary)	Examiner Name	C. Saoud	
Sheet	1	of	2	Attorney Docket Number	PF108P2	

	U.S. PATENT DOCUMENTS							
Examin Initials*	er	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
63	2	Α	5,447,841	09-05-1995	Gray et al.			
	$\neg$	В	5,491,224	02-13-1996	Bittner et al.			
		C	5,538,869	07-23-1996	Siciliano et al.			
-1		D	5,545,524	08-13-1996	Trent et al.			
V		Ε	5,837,498	11-17-1998	Olsen et al.			
(2)	2	F	5,994,301	11-30-1999	Olsen et al.			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number*-Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°		
900	G	WO 88/03949 (PCT)	06-02-1988	Howard Florey Institute of Experimental Physiology and Medicine				
ري	Н	WO 95/24411 (PCT)	09-14-1995	Human Genome Sciences, Inc.				

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>4</sup> Applicant is to place a check mark here if English language Translation is attached.

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
670	_	BUTKUS et al. "Purification and cloning of a corpuscles of stannius protein from Anguilla australis", Mol. & Cell. Endocrin. 54:123-133 (1987)			
	J	HADDAD et al. "Immunocytomchemical localization of stanniocalcin cells in the rat kidney" Endocrinol. 137(5): 2113-2117 (1996)	_		
V	К	LAFEBER et al. "Identification of hypocalcin (teleocalcin) isolated from trout stannius corpuscles", Gen. & Comparative Endocrin. 69:19-30 (1988)			
<i>D</i> D	L	MILLIKEN et al. "Effects of synthetic peptide fragments of teleocalcin (hypocalcin) on calcium uptake in juvenile rainbow trout (Salmo gairdneri)" Gen. & Comparative Endocrin. 77:416-422 (1990)	_		

Examiner Signature	Enle	Wa-	Date Considered	417/05
	71			

PTO/SB/08A (10-01)
Approved for use through 10/31/2002.OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ond to a collection of information unless it contains a valid OMB control number

Sut	Substitute for form 1449A/PTO			Complete if Known		
				Application Number	09/840,989	
11	<b>NFORMATIC</b>	N DI	SCLOSURE	Filing Date	April 25, 2001	
S	STATEMENT	BY	APPLICANT	First Named Inventor	Henrik S. Olsen	
				Art Unit	1647	
	(use as many :	sheets as	necessary)	Examiner Name	C. Saoud	
Sheet	2	of	2	Attorney Docket Number	PF108P2	

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	Γ	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
(0)	М	OLSEN et al. "Human stanniocalcin: a possible hormonal regulator of mineral		
		metabolism" PNAS USA 93:1792-1796 (1996)		
}	N	STERN et al. "Salmon stanniocalcin and bovine parathyroid hormone have dissimilar	-	
<u> </u>	ļ <u>.                                 </u>	actions on mammalian bone", J. Bone & Mineral Res. 6(11):1153-1159 (1991)		
	O WAGNER et al. "Human stanniocalcin inhibits renal phosphate excretion in the			
<u> </u>	ļ <u>.</u>	J. Bone & Mineral Res. 12(2):165-171 (1997)		
		WAGNER et al. "Molecular cloning and cDNA sequence analysis of coho salmon		
igsqcut		stanniocalcin", Mol. & Cell. Endocrin. 90(1):7-15 (1992/1993)		
	Q	WAGNER et al. "Studies on the regulation and characterization of plasma		
		stanniocalcin in rainbow trout", Mol. & Cell. Endocrin. 79:129-138 (1991)		
	R	CHANG et al. "A novel human cDNA highly homologous to the fish hormone		
		stanniocalcin", Mol Cell Endocrinol. 112(2):241-7 (1995)		
	S	MADSEN et al. "Stanniocalcin: a novel protein regulating calcium and phosphate		
$\vdash$		transport across mammalian intestine", Am J Physiol. 274(1 Pt 1):G96-102 (1998)		
1 1	T	ZHANG et al. "Stanniocalcin: a molecular guard of neurons during cerebral		
<u> </u>		ischemia", Proc Natl Acad Sci U S A. 97(7):3637-42 (2000)		
<b>l</b>	U	ZHANG et al. "High expression of stanniocalcin indifferentiated brain neurons", Am J		
<b> </b>		Pathol. 153(2):439-45 (1998)		
	V ZHANG et al. "Expression, purification, and bioassay of human stanniocalci			
1		baculovirus-infected insect cells and recombinant CHO cells", Protein Expr Purif.	<b> </b>	
$\vdash$		12(3):390-8 (1998)		
	W	BIKFALVI et al. "Biological Roles of Fibroblast Growth Factor-2", Endocrine Reviews		
		18(1):26-45 (1997)		
	X	APFEL "Neurotophic Factor Therapy-Prospects and Problems", Clin. Chem. Lab		
<del></del>	.,	Med. 39(4):351-355 (2001)		
	Y	GOLDSBY et al. "Kuby: Immunology", Cytokines 12:303-327 (2002)		
<del>                                     </del>	Z	KANDEL et al. "Principles of Neural Science", Neurotransmitters 15:280-297 (2002)	_	
<b></b>	AA	BORK et al. Trends in Genetics 12:425-427 (1996)		
	AB	BRENNER Trends in Genetics 15:132-133 (1999)		
<u> </u>	AC	SMITH et al. Nature Biotechnology 15:1222-1223 (November 1997)		
	AD	DOERKS et al. Trends in Genetics 14:248-250 (1998)		
	AE	SKOLNICK et al. Trends in Biotech. 18(1):34-39 (2000)		
<u> </u>	AF	BORK Genome Res. 10:398-400 (2000)	=	
	AG	NGO et al. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-		
V		[495 (1992)		
C27	AH	WELLS Biochem. 29:8509-8517 (1990)		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/ 1 .		Date	.//
Signature	/ // //			1417/05
Olditatule		10	Considered	
	- 1			

<sup>&#</sup>x27;Applicant's unique citation designation number (optional), 'Applicant is to place a check mark here if English language Translation is attached.